Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 7/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.52 |
| ▸ | IKZF2 | Q9UKS7 | 11/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.50 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.47 |
| ▸ | SALL4 | Q9UJQ4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21340290 | 0.94 | CRBN (0.52) | CRBNDDB1IKZF2IKZF1CSNK1A1 | |
| SCHEMBL31736792 | 0.91 | IKZF2 (0.59) | CRBNDDB1IKZF2IKZF1 | |
| SCHEMBL31025879 | 0.91 | IKZF2 (0.59) | CRBNDDB1IKZF2IKZF1 | |
| SCHEMBL31736513 | 0.91 | IKZF2 (0.59) | CRBNDDB1IKZF2IKZF1 | |
| SCHEMBL31736849 | 0.91 | IKZF2 (0.59) | CRBNDDB1IKZF2IKZF1 | |
| SCHEMBL31737024 | 0.91 | IKZF2 (0.59) | CRBNDDB1IKZF2IKZF1 | |
| SCHEMBL29583366 | 0.89 | IKZF2 (0.63) | CRBNDDB1IKZF2IKZF1 | |
| SCHEMBL20046085 | 0.89 | IKZF2 (0.63) | CRBNDDB1IKZF2IKZF1 | |
| SCHEMBL24572309 | 0.88 | IKZF2 (0.57) | CRBNDDB1IKZF2IKZF1 | |
| SCHEMBL24421502 | 0.86 | IKZF2 (0.65) | IKZF2IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111629749-A | Compositions and methods for selective protein degradation | 诺华股份有限公司 | 2020-09-04 | — | — | CN | disclosed |
| CN-111051298-A | 3- (1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2020-04-21 | — | — | CN | disclosed |